spacer
home > ict > autumn 2020 > the colours of change
PUBLICATIONS
International Clinical Trials

The Colours of Change

Some time ago, a survey was conducted on clinical trial professionals to determine what concerns worried the industry most, experts from pharmaceutical company sponsors, contract research organisations, site representatives, and vendors were consulted. Despite all the great work by these collective groups, an overwhelming number of studies fail for the simple reason that not enough patients stick with them (1). A whopping 85% of studies, in fact, according to Forte Research (2).

Once the results were assessed, ranked fourth behind the likes of trial complexity, regulatory frameworks, and increasing costs, was patient recruitment and retention.

Then, early this year, in a moment of history we are unlikely to forget, COVID-19 hit. Suddenly hospitals and healthcare facilities the world over were sent into pandemic pandemonium, and as we scrabbled for solutions many non-essential clinical trials were put on hold and their patients left in limbo.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Chris Wells is an accomplished travel specialist, event planner, creative thinker, and patient pioneer. Having spent years building programmes in the healthcare and technology sectors, Chris dedicates every minute of every day to better understand and eradicate the burden of clinical trial participation on patients and their families. As Director of Patient Concierge Services at Illingworth Research Group, their PatientGO division works tirelessly to ensure patients receive the optimum home-to-site experience. This helps to reduce study dropout, relieves the pressure on sites, and gives the medicines of the future a fighting chance of helping humanity’s most challenging and deadly diseases.

Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers

PHILADELPHIA and OXFORD, March 2, 2021 - WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide.
More info >>

White Papers

Modular Feeding Systems for Prefilled Syringes and Injection Devices

Dividella

The pre-filled syringe and injection device is an increasingly attractive presentation for both new and established parenteral pharmaceuticals. We will explore how innovative carton packaging solutions can enhance this presentation whilst meeting the stringent requirements of product protection.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement